Препараты для снижения веса: семаглутид(Wegovy), сибутрамин, орлистат. Причины ожирения. ч. 3

В этом виде расскажу про наиболее эффективные и безопасные препараты для снижения веса: Семаглутид(Оземпик, Ребелсас, Вегови), сибутрамин(редуксин, Голдлайн), орлистат.
Тайм-коды:
00:00 введение
00:51 сибутрамин
09:32 орилстат
13:25 семаглутид

Ссылки на исследования:
49. Long‐term effects of weight‐reducing drugs in people with hypertension https://www.ncbi.nlm.nih.gov/pmc/arti...
50. Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects https://www.nejm.org/doi/full/10.1056...
51. Fatal and Non-Fatal Cardiovascular Events in a General Population Prescribed Sibutramine in New Zealand https://link.springer.com/article/10....
52. Long-term Weight Loss With SibutramineA Randomized Controlled Trial https://jamanetwork.com/journals/jama...
53. Long term pharmacotherapy for obesity and overweight: updated meta-analysis - https://www.ncbi.nlm.nih.gov/pmc/arti...
54. The use of sibutramine in the management of obesity and related disorders: An update - https://www.ncbi.nlm.nih.gov/pmc/arti...
55 Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome - https://www.fertstert.org/article/S00...
56. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome - https://www.fertstert.org/article/S00...
57. Rapid Changes in Serum Testosterone in Men With Newly Diagnosed Type 2 Diabetes With Intensive Insulin and Metformin - https://www.ncbi.nlm.nih.gov/pmc/arti...
58. Weight Loss, Weight Maintenance, and Improved Cardiovascular Risk Factors after 2 Years Treatment with Orlistat for Obesity https://onlinelibrary.wiley.com/doi/1...
59. Does orlistat cause acute kidney injury? https://www.ncbi.nlm.nih.gov/pmc/arti...
60. Comprehensive Review of Current and Upcoming Anti-Obesity Drugs https://www.ncbi.nlm.nih.gov/pmc/arti...
61. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity https://www.ncbi.nlm.nih.gov/pmc/arti...
62. Safety of Semaglutide https://www.ncbi.nlm.nih.gov/pmc/arti...
63. Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide https://www.ncbi.nlm.nih.gov/pmc/arti...